Vicapsys Life Sciences, Inc. (VICP)
OTCMKTS · Delayed Price · Currency is USD
1.500
0.00 (0.00%)
At close: Dec 3, 2025

Vicapsys Life Sciences Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2023FY 2022FY 2021FY 2020FY 2019
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19
Selling, General & Admin
1.11.030.630.320.660.93
Research & Development
0.010.020.010.020.10.1
Operating Expenses
1.111.050.640.340.771.03
Operating Income
-1.11-1.05-0.64-0.34-0.77-1.03
Interest Expense
-0.21-0.14----
EBT Excluding Unusual Items
-1.26-1.18-0.64-0.34-0.77-1.03
Gain (Loss) on Sale of Investments
---0.1--
Asset Writedown
---0.34---
Pretax Income
-1.35-1.18-0.98-0.24-0.77-1.03
Earnings From Continuing Operations
-1.35-1.18-0.98-0.24-0.77-1.03
Earnings From Discontinued Operations
------0.38
Net Income
-1.35-1.18-0.98-0.24-0.77-1.41
Preferred Dividends & Other Adjustments
--0--0.16
Net Income to Common
-1.35-1.18-0.99-0.24-0.77-1.57
Shares Outstanding (Basic)
343531181711
Shares Outstanding (Diluted)
343531181711
Shares Change (YoY)
2.64%12.98%73.18%0.99%53.32%20.54%
EPS (Basic)
-0.04-0.03-0.03-0.01-0.04-0.14
EPS (Diluted)
-0.04-0.03-0.03-0.01-0.04-0.14
Free Cash Flow
-0.13-0.42-0.24-0.44-0.26-0.97
Free Cash Flow Per Share
-0.00-0.01-0.01-0.03-0.01-0.09
EBITDA
--1.02-0.61-0.31-0.73-1
D&A For EBITDA
-0.030.030.030.030.03
EBIT
-1.11-1.05-0.64-0.34-0.77-1.03
Updated Jan 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.